Buscar
Mostrando ítems 1-10 de 375
Hemorrhagic complications after off-label thrombolysis for ischemic stroke
(LIPPINCOTT WILLIAMS & WILKINS, 2007)
Background and Purpose-Only 2% to 4% of patients with acute ischemic stroke receive thrombolytic therapy resulting from the current strict inclusion criteria among other issues. Safety of intravenous and intraarterial ...
Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model.
(Elsevier B.V., 2016)
BACKGROUND:
The only pharmacological treatment with proven cost-effectiveness in reducing acute ischemic stroke (AIS) associated disability is intravenous thrombolysis with recombinant tissue plasminogen activator but ...
Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model.
(Elsevier B.V., 2016)
BACKGROUND:
The only pharmacological treatment with proven cost-effectiveness in reducing acute ischemic stroke (AIS) associated disability is intravenous thrombolysis with recombinant tissue plasminogen activator but ...
Use of Telemedicine and Other Strategies to Increase the Number of Patients That May Be Treated with Intravenous Thrombolysis
(Springer, 2012-02-01)
Stroke is the fourth leading killer in the United States and a leading cause of adult long-term disability. the American Heart Association estimates that only 3% to 5% of patients with acute ischemic stroke are treated ...
Stroke Care Within The Golden Hour
(AMER MEDICAL ASSOCCHICAGO, 2015)
Minimum intravenous thrombolysis utilization rates in acute ischemic stroke to achieve population effects on disability: A discrete-event simulation model
(Elsevier Science BV., 2016)
Background: The only pharmacological treatment with proven cost-effectiveness in reducing acute ischemic stroke (AIS) associated disability is intravenous thrombolysis with recombinant tissue plasminogen activator but it's ...
Comparative Fibrinolysis
(IntechOpen, 2014)
In this chapter we summarize the actual knowledge about fibrinolytic assays among different animal species and we compare these findings with healthy adult human beings.
Frequency, determinants, and effects of early seizures after thrombolysis for acute ischemic stroke: The ENCHANTED trial
(Lippincott Williams & Wilkins, 2017)
BACKGROUND:
Seizures after ischemic stroke have not been well-studied. We aim to determine the frequency, determinants, and significance of early seizures after thrombolysis for acute ischemic stroke.
METHODS:
Data ...
Exclusion criteria for intravenous thrombolysis in stroke mimics: an observational study
(Elsevier, 2013)
BACKGROUND:
Stroke mimics (SMs) are frequent in emergency departments (EDs), but are treated infrequently with intravenous recombinant tissue plasminogen activator (rt-PA) thrombolysis. We aimed at identifying the factors ...
Successful Intra-arterial Thrombolysis in a Patient with an Intracranial Meningioma
(Elsevier B.V., 2013-11-01)
Alteplase (recombinant tissue plasminogen activator [rt-PA]) label approval by the Food and Drug Administration remarks the contraindication of its use with known intracranial neoplasm because of potential bleeding ...